Milestone Receives FDA Approval of CARDAMYST™ (etripamil)

Why a Nasal Spray Could Change the Landscape of Arrhythmia Care

For the more than two million adults living with paroxysmal supraventricular tachycardia (PSVT), an episode can feel like a sudden, jarring sprint of the heart that lasts minutes to hours. Until now, most treatments required an IV line in an emergency department—a costly, stressful, and often delayed solution.

A New Weapon: Self‑Administered Calcium‑Channel Blocker

The FDA’s approval of CARDAMYST™ (etripamil) nasal spray introduces a rapid‑acting, prescription‑only option that patients can use at home. In the pivotal RAPID Phase 3 trial, 64 % of participants who sprayed CARDAMYST converted to sinus rhythm within 30 minutes, versus just 31 % on placebo. Median conversion time dropped from 54 minutes (placebo) to 17 minutes with the spray.

What This Means for the PSVT Market

With an estimated two million potential U.S. patients, the shift from hospital‑based IV therapy to a pharmacy‑shelf product could save the healthcare system billions in emergency‑room costs. Early market research predicts that self‑administered therapy could capture up to 30 % of the PSVT market within five years, especially among patients who avoid or delay emergency care.

From PSVT to Atrial Fibrillation with Rapid Ventricular Rate (AFib‑RVR)

Milestone’s strategy doesn’t stop at PSVT. The same etripamil molecule is moving into a Phase 3 trial for AFib‑RVR, a condition that affects an estimated ten million Americans. Roughly one‑third of AFib patients experience rapid‑rate episodes that currently demand IV therapy or cardioversion.

Regulatory Pathway: Leveraging the sNDA Route

Because the drug’s safety profile is already established for PSVT, Milestone plans to pursue a supplemental New Drug Application (sNDA) for the AFib‑RVR indication. This “boot‑strap” approach could shave 12‑18 months off the traditional approval timeline, delivering a new therapeutic option faster to a market valued at over $5 billion globally.

Potential Clinical Impact

Imagine a patient with AFib‑RVR who feels a sudden surge in heart rate; a single puff of the nasal spray could restore normal rhythm within minutes, sidestepping a trip to the ER. Real‑world evidence from the Circulation: Arrhythmia and Electrophysiology trial suggests such rapid conversion could reduce hospital admissions by up to 40 %.

Financial Foundations: Why Capital Is No Longer a Roadblock

Milestone entered a royalty purchase agreement that secured a $75 million infusion once FDA approval was obtained. As of the latest filing, the company holds over $80 million in cash and short‑term investments, positioning it to launch CARDAMYST nationwide without diluting shareholder value.

Commercialization Blueprint

Key steps include:

• Negotiating reimbursement with major insurers (expected coverage rates >80 %).
• Building a retail pharmacy distribution network across the U.S.
• Launching a patient‑education program to drive adoption and proper use.

Future Trends Shaping Arrhythmia Therapy

• Digital adherence monitoring: Wearable ECG patches can automatically confirm conversion after spray administration, feeding data back to physicians.
• Personalized dosing algorithms: AI models are being trained on real‑world data to recommend the optimal number of sprays based on patient weight, age, and comorbidities.
• Combination therapies: Ongoing trials are evaluating etripamil alongside oral beta‑blockers for synergistic rhythm control.

Frequently Asked Questions

What is CARDAMYST used for?

A prescription nasal spray (etripamil) that converts acute PSVT episodes to normal sinus rhythm.

How quickly does it work?

Clinical data show median conversion in about 17 minutes, with many patients responding within 10 minutes.

Can I use CARDAMYST if I have a pacemaker?

Patients with a permanent pacemaker may use the product, but they should discuss any concerns with their cardiologist.

Is CARDAMYST safe for people with hypertension?

The safety profile is comparable to other calcium‑channel blockers; mild nasal irritation is the most common side effect.

Will insurance cover CARDAMYST?

Milestone is actively negotiating with insurers; early indications suggest most major plans will include it in their formularies.

What’s Next for Patients and Providers?

As CARDAMYST reaches pharmacy shelves, clinicians will need to incorporate training on proper administration and post‑dose monitoring. Patients, meanwhile, will benefit from a newfound sense of control—no longer waiting for an ambulance to manage a rapid heart‑rate episode.